(24/7 MARKET NEWS) – Femasys Inc. (NASDAQ: FEMY) continues to run, following two announcements last week, including 510(k) FDA Clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube.
We covered Femasys in June, when it was trading at $0.78 and again last week, at $0.93. Femasys is now trading at $3.47, up $0.49 (+16.44%), on 4.57M premarket shares traded.
Its 52-week range is $0.2479 to $3.62. It hit $4.30 in this morning’s premarket and we would like to see it consolidate to hold its gains.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.